Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 6/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12465678 | 0.81 | SSTR5 (0.33) | PGR | |
| SCHEMBL29065303 | 0.79 | PGR (0.30) | PGR | |
| SCHEMBL8121999 | 0.74 | PTGS1 (0.36) | PTGS1PTGS2ALOX5HTR1A | |
| SCHEMBL15339580 | 0.74 | HTR1A (0.41) | PTGS1PTGS2ALOX5HTR1A | |
| SCHEMBL2692662 | 0.74 | PTGS2 (0.54) | PTGS1PTGS2ALOX5 | |
| SCHEMBL12678908 | 0.74 | PTGS1 (0.38) | PTGS1PTGS2ALOX5HTR1A | |
| SCHEMBL3307612 | 0.74 | PTGS1 (0.38) | PTGS1PTGS2ALOX5HTR1A | |
| SCHEMBL15328235 | 0.74 | TAAR1 (0.38) | PTGS1PTGS2ALOX5HTR1A | |
| SCHEMBL10440200 | 0.72 | NR3C1 (0.35) | PTGS1PTGS2ALOX5PGR | |
| SCHEMBL10440177 | 0.72 | PTGS2 (0.37) | PTGS1PTGS2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120040446-A | CDK inhibitors | 基因泰克公司 | 2025-05-27 | — | — | CN | disclosed |
| US-20220296595-A1 | CDK INHIBITORS | GENENTECH, INC. | 2022-09-22 | — | — | US | disclosed |
| CN-114364675-A | CDK inhibitors | 上海齐鲁锐格医药研发有限公司 | 2022-04-15 | — | — | CN | disclosed |
| EP-3966213-A1 | CDK INHIBITORS | Qilu Regor Therapeutics Inc. (CN) | 2022-03-16 | — | — | EP | disclosed |
| WO-2020224568-A1 | CDK INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220296595-A1 | CDK INHIBITORS | CDKL1, CDK9, CDK6 | PTGS1 1996/4885PTGS2 2925/4885ALOX5 4122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.